Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Factors influencing estimated effectiveness of COVID-19 vaccines in non-randomised studies
John P. A. Ioannidis
BMJ evidence-based medicine (2022) Vol. 27, Iss. 6, pp. 324-329
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study
Mie Agermose Gram, Hanne‐Dorthe Emborg, Astrid Blicher Schelde, et al.
PLoS Medicine (2022) Vol. 19, Iss. 9, pp. e1003992-e1003992
Open Access | Times Cited: 127
Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study
Katherine Adams, Jillian P. Rhoads, Diya Surie, et al.
BMJ (2022), pp. e072065-e072065
Open Access | Times Cited: 92
Risk and severity of SARS-CoV-2 reinfections during 2020–2022 in Vojvodina, Serbia: A population-level observational study
Snežana Medić, Cleo Anastassopoulou, Zagorka Lozanov-Crvenković, et al.
The Lancet Regional Health - Europe (2022) Vol. 20, pp. 100453-100453
Open Access | Times Cited: 78
Sources of bias in observational studies of covid‐19 vaccine effectiveness
Kaiser Fung, Mark Jones, Peter Doshi
Journal of Evaluation in Clinical Practice (2023) Vol. 30, Iss. 1, pp. 30-36
Open Access | Times Cited: 24
Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from July 12, 2021 to June 6, 2022: A prospective cohort study
Anne J. Huiberts, Brechje de Gier, Christina E. Hoeve, et al.
International Journal of Infectious Diseases (2023) Vol. 133, pp. 36-42
Open Access | Times Cited: 22
A Critical Analysis of All-Cause Deaths during COVID-19 Vaccination in an Italian Province
Marco Alessandria, Giovanni Malatesta, Franco Berrino, et al.
Microorganisms (2024) Vol. 12, Iss. 7, pp. 1343-1343
Open Access | Times Cited: 7
Does natural and hybrid immunity obviate the need for frequent vaccine boosters against SARS‐CoV‐2 in the endemic phase?
Stefan Pilz, John P. A. Ioannidis
European Journal of Clinical Investigation (2022) Vol. 53, Iss. 2
Open Access | Times Cited: 28
Effectiveness of a fourth SARS‐CoV‐2 vaccine dose in previously infected individuals from Austria
Alena Chalupka, Lukas Richter, Ali Chakeri, et al.
European Journal of Clinical Investigation (2023) Vol. 54, Iss. 3
Open Access | Times Cited: 15
COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022
Charlotte Lanièce Delaunay, Iván Martínez‐Baz, Noémie Sève, et al.
Eurosurveillance (2024) Vol. 29, Iss. 13
Open Access | Times Cited: 6
Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023–January 2024
Charlotte Lanièce Delaunay, Aryse Martins Melo, Marine Maurel, et al.
Vaccine (2024) Vol. 42, Iss. 19, pp. 3931-3937
Open Access | Times Cited: 6
Vaccine effectiveness of JCOVDEN single-dose against COVID-19 hospitalisation in Europe: an id.DRIVE test-negative case-control study
Chloé Wyndham-Thomas, E. Claire Newbern, Ainara Mira‐Iglesias, et al.
Journal of Infection and Public Health (2025) Vol. 18, Iss. 5, pp. 102700-102700
Open Access
Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states
Kathleen M. Andersen, Kristen E. Allen, Rajeev M. Nepal, et al.
Vaccine (2025) Vol. 52, pp. 126881-126881
Open Access
The Effect of HLA Polymorphism on Immune Response to SARS‐CoV‐2 Vaccination Within an Infection‐Naïve, Vulnerable Population With End‐Stage Renal Disease
F. Shinewi May Erskine, Katrina Spensley, Maria Prendecki, et al.
HLA (2025) Vol. 105, Iss. 2
Open Access
Vaccine effectiveness against SARS-CoV-2 infection and COVID-19-related hospitalization with the Alpha, Delta and Omicron SARS-CoV-2 variants: a nationwide Danish cohort study
Mie Agermose Gram, Hanne‐Dorthe Emborg, Astrid Blicher Schelde, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 26
The extent and impact of vaccine status miscategorisation on covid-19 vaccine efficacy studies
Martin Neil, Scott McLachlan, Norman Fenton
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 3
Evidence base for yearly respiratory virus vaccines: Current status and proposed improved strategies
Mariana Barosa, John P. A. Ioannidis, Vinay Prasad
European Journal of Clinical Investigation (2024) Vol. 54, Iss. 10
Open Access | Times Cited: 3
The quality and pattern of rehabilitation interventions prescribed for post-COVID-19 infection patients: A systematic review and meta-analysis
Georgia Torres, Philippe Jean-Luc Gradidge
Preventive Medicine Reports (2023) Vol. 35, pp. 102395-102395
Open Access | Times Cited: 8
Utilising biosensor‐based approaches for identifying neurotropic viruses
Mohammed Alissa, Ahmed Hjazi
Reviews in Medical Virology (2024) Vol. 34, Iss. 1
Closed Access | Times Cited: 2
COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans
Charlotte Lanièce Delaunay, Clara Mazagatos, Iván Martínez‐Baz, et al.
JAMA Network Open (2024) Vol. 7, Iss. 7, pp. e2419258-e2419258
Open Access | Times Cited: 2
Reports of Batch-Dependent Suspected Adverse Events of the BNT162b2 mRNA COVID-19 Vaccine: Comparison of Results from Denmark and Sweden
Vibeke Manniche, Max Schmeling, Jonathan D. Gilthorpe, et al.
Medicina (2024) Vol. 60, Iss. 8, pp. 1343-1343
Open Access | Times Cited: 2
COVID-19 vaccination effectiveness rates by week and sources of bias: a retrospective cohort study
Anna Ostropolets, George Hripcsak
BMJ Open (2022) Vol. 12, Iss. 8, pp. e061126-e061126
Open Access | Times Cited: 13
Effectiveness of COVID-19 Vaccines Over Time Prior to Omicron Emergence in Ontario, Canada: Test-Negative Design Study
Hannah Chung, Peter C. Austin, Kevin A. Brown, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 9
Open Access | Times Cited: 11
Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from 12 July 2021 to 6 June 2022: a prospective cohort study
Anne J. Huiberts, Brechje de Gier, Christina E. Hoeve, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 6
The test‐negative design: Opportunities, limitations and biases
Ronald Meester, J Bonte
Journal of Evaluation in Clinical Practice (2023) Vol. 30, Iss. 1, pp. 68-72
Open Access | Times Cited: 5
Population-Based Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Infection in Southern China, 2023–2024 Season
Xīn Gào, Yexiang Sun, Peng Shen, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 9
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top